human β3-adrenergic receptor

LY377604 is a human β3-adrenergic receptor agonist (EC50: 2.4 nM) and β1 2-adrenergic receptor antagonist for the study of obesity.

Ritobegron (KUC-7483), an effective and selective β3-adrenergic receptor agonist, shows effective β(3)-AR agonist activity on transfected human β-AR and has an effect on the bladder of rats Shows high selectivity with other organs.

Solabegron (GW 427353) is a selective β3-adrenergic receptor agonist that promotes cAMP accumulation in Chinese hamster ovary cells expressing the human β3-AR (EC50: 22 nM). It is used to treat overactive bladder and irritable bowel syndrome.

Ritobegron (also known as KUC-7483) is a potent and selective β3-adrenergic receptor agonist. In studies involving transfected human β-AR, Ritobegron exhibits significant and selective agonistic activity towards β(3)-AR. In rats, it shows high selectivity for the bladder over other organs. In anesthetized rats, Ritobegron effectively reduces bladder pressure with minimal impact on the cardiovascular system. It holds potential as a compound for treating overactive bladder.

L-796568 free base is a β3 adrenergic receptor agonist potentially for the treatment of obesity. L-796568 is a potent full beta(3) agonist (EC50: 3.6 nM). It has 600-fold selectivity over the human beta(1) and beta(2) receptors.

L-796568, is a β3 adrenergic receptor agonist. L-796568 is a potent full beta(3) agonist (EC(50) = 3.6 nM, 94% activation) with >600-fold selectivity over the human beta(1) and beta(2) receptors, which also displays good oral bioavailability in several